NEW YORK, January 23, 2018 /PRNewswire/ --
NetworkNewsWire Editorial Coverage
Forthe growing population of investors within the cannabis market, marijuana-related portfolios are frequently designed to be diverse - an advisable investment strategy for any trading portfolio. From the cultivation side of the cannabis sector to biotech/medical/pharmaceutical,
The subsidiary's pipeline includes two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products for a variety of ailments, such as anxiety, depression, triple negative breast cancer and fatty liver disease. CTI positions ETST in the rapidly evolving cannabinoid-based pharmaceuticals market, which Statista projects could reach $50 billion by the year 2029. Meanwhile, a report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. Discovering New Revenue Streams ETST again extended its reach in June 2017 when it entered into a joint venture to launch its wholly owned KannBidoid, Inc. ("KBD") subsidiary (http://nnw.fm/c6VBH). Positioned to take advantage of the recreational vape/smoke shop space, each of KBD's products is formulated with CBD and kanna - a small groundcover plant natively found in southern Africa - sold and distributed in the form of edibles and vapes/e-liquids products. Rooted Research & Development Though not centered on cannabis, ETST's Earth Science Pharmaceutical, Inc. subsidiary represents the core of the company's R&D capabilities. Earth Science Pharmaceutical is focused on the development of low-cost, noninvasive diagnostic tools, medical devices, testing processes, and vaccines for sexually transmitted infections (STI) and/or diseases. Its first medical device, MSN-2, is a home detection STI kit being prepared for molecular diagnostics trials. The subsidiary is managed by an executive team with years of scientific, medical and business experience in health, research and manufacturing. The expertise of this team - headed by ETST CEO and SCO Dr. Michael Aubé and COO Nickolas Tabraue - provides each of ETST's subsidiaries a multi-dimensional approach to their respective markets. Strategic Expansion via Acquisition & Partnerships In 2017 Earth Science Tech also increased operational diversity with the acquisition of Montreal-based Canna Inno Laboratories, which provides ETST access to government grants for up to half of its R&D expenditures.
Corporate Communications Contact: NetworkNewsWire (NNW) +212-418-1217 Office Editor@NetworkNewsWire.com Media Contact: FN Media Group, LLC NNW@FinancialNewsMedia.com +1(954)345-0611
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...View All